Pharma Development Summit China 2006

March 23-24 2006, Shanghai

China’s pharmaceuticals market is becoming increasingly competitive with domestic and foreign companies tackling their distribution channels.  Add to this pricing policies mandated by government and difficulties in extracting payment, the need to reform and restructure is crucial for future survival.

At the same time, China is expected to become the fifth largest drug market in the world by 2010. Growth will be driven by factors such as an increasingly ageing population, large market size (urban and rural), government initiatives to restructure the highly fragmented industry, IPR policies, as well as increasing life expectancy. China will remain an attractive location to foreign drug companies, because China offers many advantages in terms of the size of its marketplace, the relatively easy access to patients who are available for clinical trials, and lower clinical trial costs. 

Increasingly, in a highly competitive market where “supply exceeds demand”, successful and effective sales and distribution is the key challenge to develop the pharma business. 

Pharma Development Summit China 2006 is Pharma IQ’s first annual summit to focus on business development in China’s pharma industry. Real-life experiences from successful multinational and domestic pharma companies such as Novo Nordisk, Aventis, GE Healthcare and Roche will highlight lessons learnt in their business development journey. Find solutions at this conference for overcoming the challenges to ensure your business expansion in China’s highly regulated and shifting market.

Conference Manager: Vivian Tu

Tel: +86 21 5063 4538

Fax: +86 21 6859 7988

Email: enquiry@iqpc.com.cn

Website: www.iqpc.com.cn/cn-1806 (slow connecting link, but do not give up!)